Ratings by Oppenheimer (Matthew Biegler)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
7/16/2021 Nkarta Inc. NKTX New Coverage Outperform
(N/A)
27.77
(30.15)
8.57% Details
4/6/2021 Turning Point Therapeutics Inc. TPTX Maintain Outperform
(N/A)
 
 
  Details
3/24/2021 Aptose Biosciences APTO Maintain Outperform
(N/A)
 
 
  Details
1/19/2021 Fate Therapeutics FATE Maintain Outperform
(N/A)
 
 
  Details
1/12/2021 Turning Point Therapeutics Inc. TPTX Maintain Outperform
(N/A)
 
 
  Details
12/18/2020 Medicenna Therapeutics MDNA New Coverage Outperform
(N/A)
3.82
(2.55)
-33.25% Details
11/13/2020 Turning Point Therapeutics Inc. TPTX Maintain Outperform
(N/A)
 
 
  Details
11/9/2020 Fate Therapeutics FATE Maintain Outperform
(N/A)
 
 
  Details
10/26/2020 Turning Point Therapeutics Inc. TPTX Maintain Outperform
(N/A)
 
 
  Details
8/11/2020 Marker Therapeutics MRKR Maintain Outperform
(N/A)
 
 
  Details
8/11/2020 Homology Medicines FIXX Maintain Outperform
(N/A)
 
 
  Details
7/10/2020 Turning Point Therapeutics Inc. TPTX New Coverage Outperform
(N/A)
62.77
(74.47)
18.64% Details
6/10/2020 Fate Therapeutics FATE Maintain Outperform
(Outperform)
 
 
  Details
3/16/2020 Homology Medicines FIXX Upgrade Outperform
(Perform)
14.06
(8.64)
-38.55% Details
3/11/2020 Aptose Biosciences APTO Maintain Outperform
(N/A)
 
 
  Details
2/12/2020 Marker Therapeutics MRKR Maintain Outperform
(N/A)
 
 
  Details
1/17/2020 Aptose Biosciences APTO Maintain Outperform
(N/A)
 
 
  Details
12/9/2019 Fate Therapeutics FATE Maintain Outperform
(N/A)
 
 
  Details
11/13/2019 Marker Therapeutics MRKR Maintain Outperform
(N/A)
 
 
  Details
11/1/2019 Homology Medicines FIXX New Coverage Perform
(N/A)
12.84
(14.06)
9.5% Details
7/3/2019 Marker Therapeutics MRKR New Coverage Outperform
(N/A)
8.07
(1.78)
-77.94% Details
1/25/2019 Aptose Biosciences APTO New Coverage Outperform
(N/A)
2.08
(2.51)
20.67% Details